26.12.2013 Views

Staphylococcus epidermidis - virulence factors and innate ... - Munin

Staphylococcus epidermidis - virulence factors and innate ... - Munin

Staphylococcus epidermidis - virulence factors and innate ... - Munin

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

1.2.6 Antibodies in neonates<br />

Antibodies are produced by B-lymphocytes, cells in the adaptive immune system, as an adaptive<br />

response to an infection. The adaptive immune system is not generally covered in this thesis.<br />

However, as antibodies interact with the <strong>innate</strong> immune system, I will give a short description of<br />

their function in neonates. The fetus produce very little antibodies themselves due to immaturity<br />

in the adaptive immune system, poor signaling between the <strong>innate</strong> <strong>and</strong> the adaptive immune<br />

system <strong>and</strong> fetal life in a sterile environment (192). However, IgG antibodies (not IgM, IgA, IgE<br />

<strong>and</strong> IgD) are actively transported across the placenta in the last trimester of the pregnancy (192).<br />

Despite this active transfer, of antibodies, the total IgG level is lower in neonates (cord blood)<br />

than in adults (255). Furthermore, differences in transport kinetics between the IgG subclasses<br />

may cause quantitative differences in titers of IgG subclasses (191, 256), e.g. IgG1, IgG3 <strong>and</strong><br />

IgG4 are fairly efficiently transported across placenta whereas transport of IgG2 is less efficient<br />

(256, 257). Titers of maternal IgG antibody decrease gradually during the first months after<br />

birth.<br />

Preterm infants are often born before the active placental transfer of antibodies has occurred, <strong>and</strong><br />

very low antibody titers in preterm neonates increase the risk for infections (258-260).<br />

Consequently, several clinical trials have investigated the effect of pooled intravenous<br />

immunoglobulin (IVIG) administration for prevention or treatment of neonatal sepsis (261-264).<br />

Many of these trials were small <strong>and</strong> of poor quality. It has therefore for a long time been difficult<br />

to make a clear recommendation whether immunoglobulins should be a part of sepsis treatment<br />

in neonates or not. In September 2011 the results of a large r<strong>and</strong>omized controlled trial (INIS<br />

trial) including more than 3000 infants was published.(265) This study showed that therapy with<br />

IVIG had no effects on the outcome of suspected or proven sepsis (265).<br />

26

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!